Among 1608 randomized patients there were no statistically significant differences between regimens using 5-FU vs capecitabine in three-year local-regional tumor event rates ( 11.2 % vs 11.8 % ) , 5-year DFS ( 66.4 % vs 67.7 % ) , or 5-year OS ( 79.9 % vs 80.8 % ) ; or for oxaliplatin vs no oxaliplatin for the three endpoints of local-regional events , DFS , and OS ( 11.2 % vs 12.1 % , 69.2 % vs 64.2 % , and 81.3 % vs 79.0 % ) .